Teva Pharmaceutical (TEVA) and Bar Pharma (BRL) Receives Merger Approval From European Commission
Down)
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Barr Pharmaceuticals, Inc. (NYSE: BRL) have received approval from the European Commission to proceed with Teva's acquisition of Barr.
In connection with this approval, Teva and Barr are required to divest certain formulations of 17 generic drugs in certain specific countries with respect to which they have a product overlap, representing approximately $6 million in the companies' annual sales. The companies continue to expect that the transaction will close this month.
Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. [SM]
In connection with this approval, Teva and Barr are required to divest certain formulations of 17 generic drugs in certain specific countries with respect to which they have a product overlap, representing approximately $6 million in the companies' annual sales. The companies continue to expect that the transaction will close this month.
Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. [SM]
You May Also Be Interested In
- Teva Provides Updated 2012 Non-GAAP Financial Outlook; Updated 2012 Non-GAAP Diluted EPS of $5.30 to $5.40
- Barclays Comments on Wesco Aircraft Holdings (WAIR) Acquisition of Interfast; Deal Accretive to 2013
- UPDATE: Angelo, Gordon to Acquire Benihana (BNHN) for $16.30/Share in Cash
Create E-mail Alert Related Categories
Mergers and AcquisitionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
